

Join us for
an accredited
case-based
discussion on:



Severe Asthma Better Action!

A DISCUSSION ON THE RECOMMENDATIONS
FROM THE CANADIAN DELPHI CONSENSUS STUDY

Please click "Register Now" to register for the virtual session you wish to attend.
Kindly note that all the following session times are shown in Eastern Time (ET).

June 5, 2024 - Presented in English

8:00–9:30 PM ET

FACULTY

Dr. Krystelle Godbout
Dr. Alan Kaplan
Dr. Tiffany Wong

REGISTER NOW

June 11, 2024 - Presented in English

6:00–7:30 PM ET

FACULTY

Dr. Charles Chan
Dr. Alan Kaplan
Dr. Andrew O'Keefe

REGISTER NOW

June 12, 2024 - Presented in French

6:00–7:30 PM ET

FACULTY

Dr. Krystelle Godbout
Dr. Jacques Bouchard

REGISTER NOW

LEARNING OBJECTIVES

After participating in this activity,
participants will be able to:

- Proactively identify and optimize care for patients with suspected severe asthma
- Recognize strategies to assess short-acting beta agonist (SABA) overuse and repeat oral corticosteroid (OCS) therapies for severe asthma management
- Support standard and consistent treatment, management, and referral pathways for severe asthma, including biologic therapy selection

SCIENTIFIC PLANNING COMMITTEE

CHARLES K.N. CHAN (CO-CHAIR)

MD, FRCPC, FCCP, FACP
Respirologist

University Health Network
Toronto, ON

KRYSTELLE GODBOUT

MD, FRCPC
Respirologist

Laval University
Quebec City, QC

MONA LEE

MD, CCFP, FCFP
Family Physician

Lynn Valley Medical
North Vancouver, BC

ANDREW O'KEEFE (CO-CHAIR)

MD, MPH, FRCPC
Allergist

NL Allergy & Immunology,
St. Johns, NL

ALAN KAPLAN

MD, CCFP(EM), FCFP, CPC(HC)
Family Physician

University of Toronto
Toronto, ON

TIFFANY WONG

MD, FRCPC
Allergist

BC Children's Hospital
Vancouver, BC

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program (MOC) of The Royal College of Physicians and Surgeons of Canada and approved by the Canadian Thoracic Society. You may claim a maximum of 1.5 hours.

This program is co-developed by the Canadian Thoracic Society, Canadian Society of Allergy and Clinical Immunology and AstraZeneca Canada and is planned to achieve scientific integrity, objectivity and balance.

In collaboration with

